Diese Frau hat gr. Aufgeräumt, die le. 3 Jahre #Pandemie, Selbstständigkeit, neue #MS + #Immunsuppression + neue #Hilfsmittel, von 4 in 3 Ordner sortiert + sogar noch Katzis bespaßt + Spoonie-Vorrat gekocht!
Außerdem sitzt sie ganz lässig in Bruno, oder? ☺️💘♿️
“Ein Grund warum unsere Kinder derzeit die Kliniken fluten - Dank Sommerwelle ist die Schleimhautimmunität nach #COVID-19-Infektion im Eimer- Virus-induzierte #Immunsuppression der Schleimhäute mit neg. Auswirkungen auf die Funktionen der Erregeraufnahme,-erfassung und-abtötung 🧵”
“Ein Grund warum unsere Kinder derzeit die Kliniken fluten - Dank Sommerwelle ist die Schleimhautimmunität nach #COVID-19-Infektion im Eimer- Virus-induzierte #Immunsuppression der Schleimhäute mit neg. Auswirkungen auf die Funktionen der Erregeraufnahme,-erfassung und-abtötung 🧵”
@DerApotheker
Für Patient:innen mit #Immunsuppression wie #Tacrolimus muss auch beachtet werden, dass sich der Immun-Spiegel nach absetzen vom PPI ändern kann!
Wie problematisch sind #Thiazid - #Diuretika nach #Transplantation?
Vorgeschichte:
Patienten unter #Immunsuppression haben ein deutlich erhöhtes #Hautkrebs - Risiko, vor allem für den "weißen Hautkrebs". Je nach Studie ist das Risiko um den Faktor 25-60 (!) erhöht.
Was passiert nun, wenn diese Patient:innen zusätzlich Medikamente nehmen müssen, die das Hautkrebsrisiko erhöhen?
Diese Studie gibt Antworten.
Background and objectives Keratinocyte cancers, which primarily comprise squamous cell carcinomas and basal cell carcinomas, represent a major concern and potential risk for kidney transplant recipients. Hydrochlorothiazide, a diuretic widely used to treat hypertension, has been implicated in skin photosensitivity reaction. Recent studies conducted in the general population have found that hydrochlorothiazide use is associated with a higher risk of keratinocyte cancer, especially squamous cell carcinomas. High-risk groups, however, including transplant recipients were excluded from these. Our aim was to investigate whether hydrochlorothiazide use was associated with keratinocyte cancer in kidney transplant recipients on immunosuppressive therapy. Design, setting, participants, & measurements In a single-center cohort of kidney ( n =2155), combined kidney-pancreas ( n =282), and pancreas ( n =59) transplant recipients from the Données Informatisées VAlidées Transplantation (DIVAT) database transplanted between 2000 and 2017 in Nantes, France, we evaluated the association between hydrochlorothiazide exposure and keratinocyte cancers. Multivariable cause-specific, time-varying Cox models were used to estimate the relationship between hydrochlorothiazide exposure and the hazard of squamous cell carcinoma and basal cell carcinoma, with hydrochlorothiazide designated as the time-dependent variable. Results Among the participants, 279 of 2496 (11%) were exposed to hydrochlorothiazide after the transplantation. Cumulative incidence rates of keratinocyte cancer by 10 and 15 years were 7% and 9% for squamous cell carcinomas, respectively, and 8% and 11% for basal cell carcinomas, respectively. We found a relationship between exposure to hydrochlorothiazide and the risk of squamous cell carcinomas (hazard ratio, 2.04; 95% confidence interval, 1.27 to 3.28). In contrast, we found no association between hydrochlorothiazide exposure and basal cell carcinomas (hazard ratio, 0.63; 95% confidence interval, 0.35 to 1.15). Conclusions In a single-center cohort of kidney, combined kidney-pancreas, and pancreas transplant recipients, exposure to hydrochlorothiazide was associated with a two-fold higher risk of squamous cell carcinoma and no higher risk of basal cell carcinoma.
Nochmal ohne Birdsite-Link und weil es heute Nacht doch etwas untergegangen sein mag:
Ermutigende Nachrichten für die, die auf #Immunsuppression angewiesen sind, bezüglich der mRNA-#Impfung ⬇️
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort | Annals of the Rheumatic Diseases
https://ard.bmj.com/content/early/2021/03/24/annrheumdis-2021-220272
Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk of severe disease, for example, those receiving immunosuppressive therapies for chronic inflammatory cdiseases (CIDs), are prioritised for vaccination. However, data concerning generation of protective antibody titres in immunosuppressed patients are scarce. Additionally, mRNA vaccines represent a new vaccine technology leading to increased insecurity especially in patients with CID. Objective Here we present for the first time, data on the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in a cohort of immunosuppressed patients as compared with healthy controls. Methods 42 healthy controls and 26 patients with CID were included in this study (mean age 37.5 vs 50.5 years). Immunisations were performed according to national guidelines with mRNA vaccines. Antibody titres were assessed by ELISA before initial vaccination and 7 days after secondary vaccination. Disease activity and side effects were assessed prior to and 7 days after both vaccinations. Results Anti-SARS-CoV-2 antibodies as well as neutralising activity could be detected in all study participants. IgG titres were significantly lower in patients as compared with controls (2053 binding antibody units (BAU)/mL ±1218 vs 2685±1102). Side effects were comparable in both groups. No severe adverse effects were observed, and no patients experienced a disease flare. Conclusion We show that SARS-CoV-2 mRNA vaccines lead to development of antibodies in immunosuppressed patients without considerable side effects or induction of disease flares. Despite the small size of this cohort, we were able to demonstrate the efficiency and safety of mRNA vaccines in our cohort.
BeBo
Nudelholz
Edith
InI4
floatandsting
BavariaNephro
Bundestag First Said Kontext
Homer S.